Login to Your Account



Synta 'Window' Opens Wider: Breast Cancer Phase II Positive

By Randy Osborne
Staff Writer

Monday, July 29, 2013
While they are waiting for data from the non-small-cell lung cancer (NSCLC) program with Synta Pharmaceutical Corp.'s heat-shock protein 90 (Hsp90) inhibitor ganetespib, investors got a nice surprise from the Phase II effort in locally advanced or metastatic HER2-positive or triple-negative breast cancer (TNBC).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription